Stocks · News reference
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA®-Lung2) Phase II trial (PUMA-ALI-4202; NCT07465757) of alisertib in combination with
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
On Thursday, Puma Biotechnology (NASDAQ:PBYI) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive
TD Cowen analyst Marc Frahm maintains Puma Biotechnology (NASDAQ:PBYI) with a Hold and raises the price target from $5 to $6.
Puma Biotechnology (NASDAQ:PBYI) sees Q3 sales of $56.000 million-$59.000 million vs $60.500 million analyst estimate.